|
1）Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012; 61(4): 535-42
|
|
|
|
2）Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohnʼs disease. Gastrointest Endosc. 2006; 63(3): 433-42; quiz 64
|
|
|
|
|
|
3）Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15(9): 1295-301
|
|
|
|
|
|
4）Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138(2): 463-8; quiz e10-1
|
|
|
|
|
|
5）Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012; 142(5): 1102-11 e2
|
|
|
|
|
|
6）Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141(4): 1194-201
|
|
|
|
|
|
7）Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013; 37(10): 998-1004
|
|
|
|
|
|
8）Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011; 17(8): 1759-68
|
|
|
|
|
|
9）Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7(8): 874-81
|
|
|
|
|
|
10）Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohnʼs disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010; 8(8): 655-9
|
|
|
|
|
|
11）Van Assche G, Magdelaine-Beuzelin C, DʼHaens G, et al. Withdrawal of immunosuppression in Crohnʼs disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008; 134(7): 1861-8
|
|
|
|
|
|
12）Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohnʼs disease treated with combination therapy. Am J Gastroenterol. 2010; 105(5): 1142-9
|
|
|
|
|
|
13）Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010; 32(9): 1129-34
|
|
|
|
|
|
14）Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012; 142(1): 63-70 e5; quiz e31
|
|
|
|
|
|
15）Afif W, Loftus EV, Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105(5): 1133-9
|
|
|
|
|
|
16）Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11(4): 444-7
|
|
|
|
|
|
17）Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23): 2462-76
|
|
|
|
|
|
18）Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohnʼs disease. Gut. 2009; 58(7): 940-8
|
|
|
|
|
|
19）Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease. Inflamm Bowel Dis. 2009; 15(6): 816-22
|
|
|
|
|
|
20）Gonzaga JE, Ananthakrishnan AN, Issa M, et al. Durability of infliximab in Crohnʼs disease: a single-center experience. Inflamm Bowel Dis. 2009; 15(12): 1837-43
|
|
|
|
|